Urelumab

Phase 2Monoclonal antibody

Bristol-Myers Squibb

Urelumab is one of 176 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

175

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

B-Cell Non-Hodgkins LymphomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

LymphomaPhase 2

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 1

Active, not recruiting

B-Cell Non-Hodgkins LymphomaPhase 1

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Urelumab

Bristol-Myers Squibb

Phase 2

2 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma2 trials

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01471210·124 enrolled

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02253992·232 enrolled

Stereotactic Body Radiotherapy1 trial

Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

Completed·UUniversity of Chicago·Phase 1·NCT03431948·60 enrolled

Multiple Myeloma1 trial

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02252263·44 enrolled

Adenocarcinoma1 trial

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02451982·76 enrolled

Metastatic Colorectal Cancer1 trial

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02110082·66 enrolled

3 more indications

Chronic Lymphocytic Leukemia1 trial

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02420938

Malignant Tumors1 trial

Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02534506·18 enrolled

B-cell non-Hodgkins lymphoma1 trial

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01775631·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Urelumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Urelumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Urelumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

Urelumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma2 trials

Stereotactic Body Radiotherapy1 trial

Multiple Myeloma1 trial

Adenocarcinoma1 trial

Metastatic Colorectal Cancer1 trial

Chronic Lymphocytic Leukemia1 trial

Malignant Tumors1 trial

B-cell non-Hodgkins lymphoma1 trial

References

Drug Info

Quick Facts

Related News